Convergent to present prostate cancer research at ASCO

By staff writers

May 25, 2023 -- Biotechnology company Convergent Therapeutics will present a prostate cancer research findings at the American Society of Clinical Oncology (ASCO) annual meeting, June 2 to 6 in Chicago.

The research will describe the company's CONV01-α (actinium-225 J591), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to actinium-225. It will be presented June 3 by Dr. Scott Tagawa from Weill Cornell Medicine and will also be available on demand.

Copyright © 2023

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking